Literature DB >> 9833883

Growth properties of HSIVnef: HIV-1 containing the nef gene from pathogenic molecular clone SIVmac239.

K Yoon1, H W Kestler, S Kim.   

Abstract

To elucidate the function of nef, we constructed infectious chimeric clones between human immunodeficiency virus type 1 (HIV-1) and simian immunodeficiency virus (SIV) of macaques, by deleting a part of the nef sequence from the HIV-1 genome and inserting the entire nef gene from the pathogenic molecular clone, SIVmac239. We have named this construct HSIVnef. While there was no difference in the replication kinetics of HSIVnef+ and HSIVnef- in transformed cell lines, there was a profound difference in the replication of these virus in primary cells. These data indicated that the SIV nef gene could complement the functions of the HIV-1 nef gene in the context of the HIV-1 genome, providing further evidence that results observed in the macaque model are relevant to HIV infections in man. HSIVnef is a useful model for the study of the nef gene.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9833883     DOI: 10.1016/s0168-1702(98)00076-8

Source DB:  PubMed          Journal:  Virus Res        ISSN: 0168-1702            Impact factor:   3.303


  3 in total

Review 1.  The Vpu protein: new concepts in virus release and CD4 down-modulation.

Authors:  Autumn Ruiz; John C Guatelli; Edward B Stephens
Journal:  Curr HIV Res       Date:  2010-04       Impact factor: 1.581

2.  Chimeric human immunodeficiency virus type 1 virions that contain the simian immunodeficiency virus nef gene are cyclosporin A resistant.

Authors:  Mahfuz Khan; Lingling Jin; Lesa Miles; Vincent C Bond; Michael D Powell
Journal:  J Virol       Date:  2005-03       Impact factor: 5.103

3.  Chimeric human immunodeficiency virus type 1 (HIV-1) virions containing HIV-2 or simian immunodeficiency virus Nef are resistant to cyclosporine treatment.

Authors:  Mahfuz Khan; Lingling Jin; Ming Bo Huang; Lesa Miles; Vincent C Bond; Michael D Powell
Journal:  J Virol       Date:  2004-02       Impact factor: 5.103

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.